Mecasermin

Generic Name: Mecasermin

Brand Names: Increlex

Drug Type: Biotech

Chemical Formula: -

CAS Number: 68562-41-4

Unique Ingredient Identifier: 7GR9I2683O

Background: Mecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1). IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. The amino acid sequence of the product is identical to that of endogenous human IGF-1. The rhIGF-1 protein is synthesized in bacteri...

Indication: For the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH . It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy.

Associated Conditions: Primary Insulin-like Growth Factor-1 Deficiency

Associated Therapies: -

Clinical Trials

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

Eton Pharmaceuticals acquired Increlex®, a biologic treatment for severe primary insulin-like growth factor 1 deficiency in pediatric patients, expanding its pediatric endocrinology portfolio. Increlex® is now available in the U.S. through AnovoRx, a specialty pharmacy for rare and chronic conditions, and will be commercialized by Eton after a six-month transition period.

pipelinereview.com

3 months ago

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

Eton Pharmaceuticals to acquire Increlex® from Ipsen, aligning with its mission to develop life-changing treatments for ultra-rare conditions. Increlex treats severe IGF-1 deficiency in children and adolescents, approved in 40 territories. Eton will commercialize in the U.S. immediately, with a six-month transition period outside the U.S. Financed by Eton’s cash and credit facility expansion, Ipsen reported €17.3 million in global sales for Increlex in 2023.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy